Genfit is conducting the RESOLVE-IT clinical research study to evaluate whether an investigational medication called elafibranor can effectively treat and prevent disease progression in adults who have nonalcoholic steatohepatitis (NASH).
NASH is a progressive liver disease linked to diabetes and obesity. The condition is characterized by a buildup of fat in the liver (steatosis), as well as inflammation and degeneration of liver cells. Scarring (fibrosis) of the liver begins to occur when damaged tissue replaces healthy liver tissue.
If you are obese or have type II diabetes, or if you have previously been diagnosed with NASH, you may be eligible to participate in the RESOLVE-IT Research Study.
To qualify, participants must:
- Be between 18 and 75 years old
- Have been diagnosed with or be at risk for NASH with fibrosis
- Be willing to have a liver biopsy before enrolling in the study to confirm severity of NASH, or have already had a liver biopsy in the past 6 months
Participants may receive:
Qualified participants will receive a no-cost medical evaluation that will assess the health of your liver, and may receive the investigational medication for up to 6 years.